Galapagos Knocked By Knee Osteoarthritis Fail
Servier-Partnered Drug Shows No Activity in Phase II
Executive Summary
Still reeling from the FDA rejection of its JAK inhibitor filgotinib for rheumatoid arthritis, the Belgium-headquartered biotech's ADAMTS-5 inhibitor developed with France's Servier is sunk after failing to significantly reduce cartilage loss compared with placebo in an OA trial.
You may also be interested in...
Galapagos Sells CRO To Selvita For €31.2m
The Belgian biotech has divested its drug discovery services unit in Croatia which was making a nice profit but was not a priority as Galapagos concentrates on setting up its commercial operations in Europe.
Y-mAbs Gives Thanks For First Approved Drug Danyelza
US regulators refused to accept the file for one of Y-mAbs's neuroblasoma drugs – omburtamab – in October but have given the green light to a second one, naxitamab.
Biogen Bets Big To Bag Sage Depression And Tremor Drugs
Rather than hitting the acquisition trial, Biogen has taken the licensing route to expand its psychiatric and neurological disorders pipeline.
Need a specific report? 1000+ reports available
Buy Reports